Tolerability of two different combinations of antiretroviral drugs including tenofovir used in occupational and nonoccupational postexposure prophylaxis for HIV

AIDS Patient Care and STDs

Volumn 24, Issue 1, 2010, Pages 1-3

  Burty, Christine ^a   Prazuck, Thierry ^b   Truchetet, Francois ^a   Christian, Bernard ^a   Penalba, Christian ^a   Salmon Ceron, Dominique ^c   Yazdanpanah, Yazdan ^d   May, Thierry ^a   Rabaud, Christian ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b CENTRE HOSPITALIER RÉGIONAL D ORLÉANS   (France)

^c CHU Cochin Tarnier ^*  (France)

^d CENTRE HOSPITALIER DE TOURCOING   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; STAVUDINE; TENOFOVIR;

DRUG CAPSULE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; INOCULATION; LACTIC ACIDOSIS; LETTER; LIPOATROPHY; LIVER FAILURE; NEPHROLITHIASIS; NONHUMAN; PROPHYLAXIS; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION; VIRUS TRANSMISSION;

ADENINE; ADULT; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, PATIENT-TO-PROFESSIONAL; MALE; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HEALTH SERVICES; PATIENT COMPLIANCE; PHOSPHONIC ACIDS;

EID: 76649097008     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2009.0263     Document Type: Letter

References (11)

1. Cardo DM, Culver DH, Ciescalski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med 1997;37:1485-1490.
2. Ministère des Affaires Sociales, du Travail et de la Solidarité, 2003. Circulaire DGS=DHOS=DRT=DSS=SD6A n8 2003-2165 du 2 avril 2003 relative aux recommandations de mise en oeuvre d'un traitement antirétroviral après exposition au.
3. Lee LM, Henderson DK. Tolerability of postexposure antiretrovial prophylaxis for occupational exposures to HIV. Drug Saf 2001;24:587-597.
4. Quirino T, Niero F, Ricci E, et al. HAART tolerability: postexposure prophylaxis in healthcare workers versus treatment in HIV-infected patients. Antivir Ther 2000;5:195.
5. Parkin JM, Murphy M, Anderson J, El-Gadi S, Forster G, Pinching AJ. Tolerability and side-effects of post-exposure prophylaxis for HIV infection. Lancet 2000;355:722-723.
6. Rabaud C, Bevilacqua S, Beguinot I, et al. CISIH Nancy Lorraine Champagne-Ardenne, France. Tolerability of postexposure zidovudine+lamivudine+nelfinavir prophylaxis of HIV infection. Clin Infect Dis 2001;32:1494-1495.
7. Rabaud C, Burty C, Grandidier M, et al. Tolerability of post-exposure prophylaxis of HIV infection with the combination of zidovudine=lamivudine and lopinavir=ritonavir (Combivir+Kaletra). Clin Infect Dis 2005;40:303-305.
8. Centers for Disease Control and Prevention. Serious adverse events attribued to nevirapine regimens for postexposure prophylaxis after HIV exposures worldwide, 1997-2000. MMWR Morb Mortal Wkly Rep 2001;49:1153-1156.
9. Van Rompay KK, McChesney MB, Aguirre NL, et al. Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infections. J Infect Dis. 2001;184:429-438.
10. Subbarao S, Otten RA, Ramos A, et al. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis 2006;194:904-911.
11. Rapport du Groupe d'Experts 2008 sur la prise en charge médicale des patients infectées par le VIH, sous la direction du Pr Patrick Yéni. Prise en charge des situations d'exposition au risque viral. www.sante-sports.gouv.fr=IMG==pdf= 18-Prise-en-charge-des-situations-d- exposition-au-risque- viral.pdf (Last accessed October 26, 2009).